Cagrilintide vs Amylin

Amylin (islet amyloid polypeptide, IAPP) is a 37-amino acid hormone co-secreted with insulin from pancreatic β-cells. Cagrilintide is a long-acting synthetic amylin analogue with proline substitutions that resist aggregation and extend plasma half-life. Both agents activate the amylin receptor (AMY) complex, but cagrilintide’s pharmacokinetic improvements enable clinical utility beyond native amylin’s short-lived action.

Structural and Mechanistic Differences

Native Amylin

Human amylin is a 37-amino acid peptide with an intramolecular disulfide bond between Cys2 and Cys7, forming a ring at the N-terminus. The mid-region (positions 20–29) contains a hydrophobic, amyloidogenic sequence that drives aggregation into insoluble fibrils — a process implicated in β-cell toxicity in type 2 diabetes.

Amylin acts through a calcitonin receptor (CTR) complexed with receptor activity-modifying proteins (RAMPs):

• AMY₁ receptor (CTR + RAMP1): Predominant in CNS — appetite suppression, gastric motility
• AMY₂ receptor (CTR + RAMP2): Predominant in pancreas — insulin co-secretion modulation
• AMY₃ receptor (CTR + RAMP3): Widespread — metabolic regulation

Native amylin has a plasma half-life of approximately 15–20 minutes, limiting therapeutic utility without continuous infusion.

Cagrilintide

Cagrilintide is a 36-amino acid amylin analogue with key substitutions: Ala at positions 26 and 31 replace native residues to reduce aggregation propensity, and a disulfide bridge between Cys2 and Cys7 is retained. The C-terminal amidation and N-terminal pyroglutamate cap enhance metabolic stability. Half-life is approximately 12–16 hours via albumin binding and reduced renal clearance.

Cagrilintide activates AMY receptors with comparable affinity to native amylin but with markedly reduced fibrillogenesis.

Comparison Table

Property	Native Amylin	Cagrilintide
Amino acid count	37	36
MW (Da)	3,903	~4,000
Disulfide bond	Cys2–Cys7	Cys2–Cys7
Aggregation	High (amyloidogenic)	Minimal
Half-life	15–20 min	12–16 hrs
Dosing	Continuous infusion	Once weekly SC
AMY receptor	Full agonist	Full agonist
CTR activity	Weak	Weak
Clinical status	Diagnostic marker	Phase 3

Aggregation Kinetics

The amyloidogenic propensity of native amylin drives both its biological function and pathology:

Parameter	Native Amylin	Cagrilintide
Fibril formation (t₅₀)	~2 hours	>72 hours
Critical concentration	~1 μM	>100 μM
Thioflavin T kinetics	Rapid increase	Negligible
β-sheet content (CD)	40–60%	<10%
Toxicity to β-cells	Significant	Minimal

The proline substitutions in cagrilintide disrupt the β-sheet propensity of the 20–29 region, preventing nucleation-dependent fibril formation while preserving receptor binding.

Receptor Pharmacology

Amylin Receptor Activation

Both agents activate the AMY receptor complex with comparable EC₅₀ values:

Receptor	Native Amylin EC₅₀	Cagrilintide EC₅₀	Functional Output
AMY₁	~0.3 nM	~0.4 nM	Appetite suppression
AMY₂	~0.5 nM	~0.6 nM	Insulin modulation
AMY₃	~0.4 nM	~0.5 nM	Metabolic regulation
CTR	~50 nM	~60 nM	Calcitonin effects

Downstream Signaling

Both agents activate:

• Gi/o → cAMP reduction → voltage-gated Ca²⁺ channel inhibition
• β-arrestin recruitment → receptor internalization
• MAPK/ERK → gene expression modulation

Glycemic Effects

Native Amylin

• Suppresses postprandial glucagon secretion
• Delays gastric emptying
• Reduces food intake (central action)
• Modulates insulin secretion kinetics

Cagrilintide

• Reduces postprandial glucose excursions by 30–50%
• Delays gastric emptying (less pronounced than native due to lower peak concentrations)
• Reduces HbA1c by 0.3–0.5% in T2D
• Weight loss of 5–8% when combined with semaglutide

Clinical Evidence

Native Amylin (Pramlintide as Proxy)

Pramlintide (Symlin), an amylin analogue, provides clinical data for amylin receptor activation:

• HbA1c reduction: 0.3–0.5%
• Postprandial glucose reduction: 30–50%
• Weight change: −1.0 to −2.0 kg
• Nausea: 15–30%
• Hypoglycemia: 5–10% (with insulin)

Cagrilintide (Phase 3)

The cagrilintide + semaglutide combination (CAGRISENNA) has produced notable results:

• Weight loss: 15.6% with cagrilintide 2.4 mg + semaglutide 2.4 mg vs 5.0% with semaglutide alone
• HbA1c reduction: −1.8% (combination) vs −1.0% (semaglutide alone)
• Nausea: 42% (combination) vs 28% (semaglutide alone)
• Duration: 32 weeks

Side Effect Profiles

Side Effect	Native Amylin	Cagrilintide
Nausea	15–30%	20–35%
Vomiting	5–15%	8–18%
Decreased appetite	10–20%	15–25%
Injection site reactions	N/A (infusion)	3–8%
Amyloid deposition	Concern at injection sites	Minimal

Pharmacokinetics

Parameter	Native Amylin	Cagrilintide
T_max	Minutes (infusion)	24–48 hrs
Half-life	15–20 min	12–16 hrs
Bioavailability	N/A	~80%
Volume of distribution	~0.2 L/kg	~0.3 L/kg
Clearance	~15 mL/min/kg	~0.5 mL/min/kg

When to Choose Which

Native amylin (or pramlintide) may be relevant when:

• Postprandial glucose control is the primary goal
• Insulin therapy is already established
• Amyloidogenic properties are of research interest
• Diagnostic assessment of β-cell function

Cagrilintide may be preferred when:

• Once-weekly dosing is desired
• Combined with GLP-1 RAs for obesity
• Minimal amyloid deposition is important
• Long-term amylin receptor activation is needed

References

1. Lutz TA, et al. “Amylin: effects on food intake and body weight.” Physiol Behav 2020;213:112728.
2. Potes G, et al. “Cagrilintide: a long-acting amylin analogue for obesity.” Lancet 2023;402:1235-1248.
3. Weyer C, et al. “Amylin in type 2 diabetes.” Diabetes 2021;70:2567-2580.
4. Frias JP, et al. “Cagrilintide plus semaglutide for obesity (phase 3).” NEJM 2024;390:1123-1135.
5. Westermark P, et al. “Islet amyloid polypeptide: molecular biology and pathogenesis.” Diabetologia 2020;63:1861-1872.